The cabotegravir pellet implant with levonorgestrel is a long-acting multipurpose prevention technology implantable product developed by CONRAD combining cabotegravir, for HIV prevention, and levonorgestrel, for contraception, in a biodegradable subdermal pellet system. This product is a low-cost, biodegradable subdermal pellet-type implant system that provides tightly controlled, long-acting sustained release of its payload, is highly tunable, and does not require surgical removal.

*Also referred to as a dual-prevention product by MATRIX